Response to "Survival advantage for Etoposide/Cisplatin over Paclitaxel/Carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: A subgroup analysis for ECOG 2 patients would be of great interest"

    Annals of oncology : official journal of the European Society for Medical Oncology, 2017.

    Cited by: 0|Bibtex|Views0|Links
    WOS
    Keywords:
    Chemoradiotherapyconcomitantinoperablelocally-advanced NSCLCperformance status

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments